B+
Bull case
30%
Probability
Target price
$82.00
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
PTCT
PTC TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The post-earnings bull case is that Sephience launch momentum is proving stronger and broader than expected, the Q1 beat justified a guidance raise, and votoplam plus the disclosed $50M Novartis milestone add pipeline-backed cash support. PTCT also traded materially above the 2026-05-07 anchor after the release, consistent with a favorable initial market read.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +9.3.
What can break
Emflaza revenue fell year over year due to continued generic erosion, offsetting part of the broader portfolio strength.
Momentum
8
Value
53
Sentiment
69
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $72.00 · Bull $82.00 · Bear $54.00Analysis 2026-05-09; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-09 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $99.29
Why
Momentum8 · Δ7d -0.3
Value53 · Δ7d -0.0
Sentiment69 · Δ7d +9.3
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +9.3.
Contradictions & invalidation
- • Emflaza revenue fell year over year due to continued generic erosion, offsetting part of the broader portfolio strength.
- • PTC had $287.5M principal of 1.50% convertible senior notes due September 15, 2026 outstanding as of March 31, 2026; liquidity is strong, but the maturity remains a capital-structure item to monitor [#10-Q-2026-05-07].
- • The bear case is that this is still a monitoring story rather than a de-risked rerating: Emflaza continues to erode, Translarna revenue remains exposed to lumpiness and regulatory overhang, vatiquinone still needs a new study after the prior CRL, and delayed analyst target/rating revision evidence was not clearly available in the checked sources.
Catalyst clock
2026-05-07
Q1 beat and 2026 revenue guidance raise reset near-term expectations
Lead driver: Sentiment · See AI snapshot
Momentum
8
9% active weight
Current posture
7d trendFlat
Δ7d
-0.3
Δ21d
-7.1
Value
53
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-5.9
Sentiment
69
62% active weight
Current posture
7d trendImproving
Δ7d
+9.3
Δ21d
+8.9
Why this grade
Composite grade C. Momentum 8.3 / Value 53.4 / Sentiment 68.9
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-09. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$72.00
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$54.00
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$6.08B
Beta
0.48
Shares Out
83.46M
P/E (TTM)
9.0
P/S (TTM)
3.46
P/FCF (TTM)
8.74
Rev YoY
+101.5%
EPS YoY
-210.6%
Gross Margin
+89.0%
Op Margin
+11.6%
Net Debt
-$1.55B
Current Ratio
3.39
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data